Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.40 |
| ▸ | GPR4 | P46093 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 3/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30984061 | 0.89 | HRH4 (0.48) | HRH4EPHX2GPR4RETDRD3 | |
| SCHEMBL30983802 | 0.81 | CNR1 (0.43) | EPHX2GPR4RETDRD3SQOR | |
| SCHEMBL30983836 | 0.79 | CNR1 (0.41) | EPHX2GPR4RETDRD3SQOR | |
| SCHEMBL30983929 | 0.79 | GPR4 (0.40) | EPHX2GPR4RETGPR119SQOR | |
| SCHEMBL30983841 | 0.79 | CNR1 (0.41) | EPHX2GPR4RETDRD3SQOR | |
| SCHEMBL30983856 | 0.79 | CNR1 (0.41) | EPHX2GPR4RETSQOR | |
| SCHEMBL30983875 | 0.79 | CNR1 (0.41) | EPHX2GPR4RETDRD3GPR119 | |
| SCHEMBL30983893 | 0.78 | CNR1 (0.42) | HRH4EPHX2GPR4 | |
| SCHEMBL30983971 | 0.76 | HRH4 (0.49) | HRH4 | |
| SCHEMBL31321946 | 0.73 | DGAT1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| US-12414954-B2 | POLQ inhibitors | ASTRAZENECA AB (SE) | 2025-09-16 | — | — | US | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024121753-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12414954-B2 | POLQ inhibitors | POLQ, POLG, POLB | HRH4 4696/4885EPHX2 3565/4885GPR4 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.